Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887234 | 0.90 | HDAC1 (0.42) | LMNASMN1; SMN2HDAC1GAAKMT2A | |
| SCHEMBL5887531 | 0.88 | HDAC1 (0.42) | OPRK1HDAC1GAAJAK2JAK1 | |
| SCHEMBL5887131 | 0.87 | HDAC1 (0.40) | LMNASMN1; SMN2OPRK1HDAC1KMT2A | |
| SCHEMBL5887537 | 0.85 | ALDH1A1 (0.41) | LMNASMN1; SMN2MAPK8HDAC1KMT2A | |
| SCHEMBL5887359 | 0.85 | MAOA (0.41) | LMNASMN1; SMN2HDAC1 | |
| SCHEMBL5887403 | 0.84 | PDE4B (0.39) | OPRK1HDAC1KMT2AMEN1 | |
| SCHEMBL5887193 | 0.83 | SMN1; SMN2 (0.43) | LMNASMN1; SMN2TP53 | |
| SCHEMBL5887380 | 0.83 | PPARG (0.41) | LMNAMAPK8HDAC1KMT2ATP53 | |
| SCHEMBL5887437 | 0.83 | LMNA (0.57) | LMNASMN1; SMN2GAAKMT2ATSHR | |
| SCHEMBL5887427 | 0.79 | SMN1; SMN2 (0.46) | LMNASMN1; SMN2MAPK8GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | LMNA 711/4885SMN1; SMN2 2219/4885OPRK1 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.